Ligand Pharmaceuticals Incorporated
LGNDLigand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
Drugs in Pipeline
9
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How LGND's past catalysts played out
lasofoxifene
Osteoporosis
LGD-6972-5 mg
Type 2 Diabetes Mellitus
MB07803
Type 2 Diabetes Mellitus
MB07133 300mg/m2/day
Hepatocellular Carcinoma
bexarotene
Breast Cancer
denileukin diftitox
Drug/Agent Toxicity by Tissue/Organ
PS433540
Hypertension
irbesartan
Hypertension
Aplindore
Early Stage Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lasofoxifene | Phase 3 | Osteoporosis | - | - |
LGD-6972-5 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MB07803 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MB07133 300mg/m2/day | Phase 2 | Hepatocellular Carcinoma | - | - |
bexarotene | Phase 2 | Breast Cancer | - | - |
denileukin diftitox | Phase 2 | Drug/Agent Toxicity by Tissue/Organ | - | - |
PS433540 | Phase 2 | Hypertension | - | - |
irbesartan | Phase 2 | Hypertension | - | - |
Aplindore | Phase 2 | Early Stage Parkinson's Disease | - | - |
Frequently asked questions
What is in Ligand Pharmaceuticals Incorporated's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Ligand Pharmaceuticals Incorporated's (LGND) pipeline across Phase 3, Phase 2. Its lead program is lasofoxifene (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ligand Pharmaceuticals Incorporated's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ligand Pharmaceuticals Incorporated (LGND) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LGND biotech catalysts?→
Add LGND to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ligand Pharmaceuticals Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.